The Evolving Landscape of Factor Replacement Therapy – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD) shared a post on LinkedIn:
“Summer is the perfect time to catch up on the educational content you’ve been meaning to watch and stay up to date with the latest developments in haemophilia care.
One topic that continues to evolve rapidly is factor replacement therapy.
As treatment options expand, choosing the most appropriate factor VIII and factor IX replacement products and understanding how monitoring is changing has become increasingly important for delivering personalised care.
In this recorded session, Jan Astermark, Annette Bowyer and Cedric Hermans (Lon,Edin) examine the latest evidence, discuss the expanding therapeutic landscape, and explore how monitoring is evolving to support more precise, individualised treatment decisions.
What session is next on your summer learning list?”
Other posts about European Association for Haemophilia and Allied Disorders on Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM